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Sustained progression on the expanded disability status scale (EDSS) is a common outcome measure of disease progression in
clinical studies of MS. Unfortunately, this outcome may not accurately measure long-term and irreversible disease progression. To
assesstheperformanceofdefinitionsofsustainedprogression,patientswithrelapsing-remittingMS(RRMS)oraclinicallyisolated
syndrome with evidence of lesions on a brain MRI were included in our study. Fifteen definitions of sustained progression using
both the EDSS and the functional system (FS) scales were investigated. The impact of both relapses and changes in provider on
theprobability ofmaintaining progressionwas alsoevaluated. Althoughthe provider scoring theEDSS sometimes changed during
followup,theproviderhadaccesstopreviousEDSSscores.Between15.8%and42.2%ofpatientsexperiencedsustainedprogression
based on the definitions using EDSS as the outcome, but nearly 50% of these patients failed to maintain sustained progression
for the duration of followup. When FS scales were used, progression was most common on the pyramidal and sensory scales.
Unfortunately,progressiononspecificFSscalesfailedtobemoresensitivetoirreversibledisability.Relapsesorchangesinprovider
didnotexplainthepoorperformanceofthemeasures.Short-termchangesintheEDSSorFSscoresmaynotbeanaccuratemarker
of irreversible change in RRMS.
1. Introduction
Measurementofdiseaseprogressioninpatientswithmultiple
sclerosis (MS) is complicated by the occurrence of relapses
and the potential for recovery, especially early in the disease
course in patients with relapsing-remitting MS (RRMS). The
most common way to measure disability in MS patients
is the expanded disability status scale (EDSS), which is a
0–10 scale with 0.5 point steps based on eight functional
system(FS)scales[1].TheseFSscalesmeasuresevenseparate
aspects of the disease using five-to seven-step ordinal scales:
pyramidal function, cerebellar function, brainstem function,
sensory function, bowel/bladder function, mental function,
and visual function. The remaining scale is a measure of the
presence of other symptoms. In long-term followup studies,
EDSS scores of 4, 6, or 7 are considered milestones in terms
of disability, and reaching these milestones is a measure of
disease progression, especially since patients rarely improve
after such milestones are reached [2, 3]. Since the time to
these EDSS scores is often long, a short-term indicator of
d i s e a s ep r o g r e s s i o ne a r l yi nt h ed i s e a s ec o u r s ei sa ni n c r e a s e
in EDSS score that is sustained over several months. This
is called sustained disease progression. Sustained disease
progression is required because transient increases in the
EDSS may also be due to relapses [4], which reflect disease
activity rather than disease progression. However, there is
still controversy over an optimized definition of short-term
disease progression [5].
The ideal measure of sustained progression would accu-
rately identify patients with true disease progression that
would not revert given additional followup. Several defini-
tions of sustained progression for clinical trials and observa-
tional studies have been proposed, but a one-point increase2 Multiple Sclerosis International
sustained for at least three or six months for patients with
an EDSS of less than 6 (sometimes a 1.5-point increase
for EDSS = 0) or an increase of 0.5 for patients with an
E D S So f6o rg r e a t e ri sp r o b a b l yt h em o s tc o m m o n[ 6, 7].
Unfortunately, many patients who fulfill this criterion for
sustained progression fail to maintain elevated EDSS scores
later in the disease course, demonstrating that this outcome
does not correctly identify patients with true irreversible
disease worsening [8, 9]. Definitions using alternative EDSS
changes or time intervals have also been investigated, but
no perfect definition has been developed [10]. One potential
difficulty for definitions of sustained progression is the
complex relationship between changes on specific FS scales
a n dc h a n g e so nt h eE D S Ss c a l e ,e s p e c i a l l yi np a t i e n t sw i t h
mild disability. Therefore, alternative definitions of sustained
progression may more accurately measure irreversible dis-
ability accumulation, and these may provide better outcomes
for clinical trials and clinical research studies.
In this paper, several definitions of disease progression
based on the EDSS are assessed, and additional definitions
based on the FS scales are explored. For each outcome,
the distribution of time to progression was estimated to
determine the pattern of disability accumulation in a group
ofMSpatients.Then,thelikelihoodofmaintainingsustained
progression for the remainder of followup was estimated
to evaluate the performance of each outcome. Third, the
p o t e n t i a li m p a c to fr e l a p s e sa n dc h a n g e si np r o v i d e ro n
the performance of these definitions was assessed. Finally,
the implications of the results for clinical trials focused on
sustained progression are discussed.
2. Materials and Methods
2.1. Subjects. All patients with RRMS or a clinically isolated
syndrome (CIS) with evidence of lesions on a brain MRI
enrolled in the comprehensive longitudinal investigation of
multiple sclerosis at the Brigham and Women’s Hospital and
Partners MS Center (CLIMB) as of 3/1/2012 were eligible for
our study [11]. Patients were also required to have a baseline
EDSS of less than 6 to focus attention on patients likely to
be enrolled in clinical trials of RRMS. CLIMB patients have
clinical visits every six months. At each clinical visit, a com-
pleteneurologicalexamiscompletedincludingmeasurement
oftheEDSSandeachoftheFSscales.TheEDSSandFSscales
can be scored by different providers at different visits, and
the previous EDSS and FS scores are available to the rating
provider. For our analysis of sustained progression, patients
needed to have at least 1 year of followup. This restriction
yielded a final sample of 929 patients. The baseline demo-
graphicandclinicalcharacteristicsofoursampleareprovided
in Table 1, and a flow chart of patient enrollment is provided
in Figure 1. The mean (SD) followup time was 3.7 (2.5) years.
This study has received IRB approval from our institution.
2.2. Clinical Measures/Definitions of Progression. The clinical
outcomemeasuresinourstudyweretheEDSSandFSscores,
and definitions of sustained progression were based on these
measures. The first four definitionsused the EDSS as the out-
come,andaspecificincreaserelativetobaselinewasrequired
Table 1: Baseline demographic and clinical characteristics in study
sample.
𝑁 929
Gender (% female) 75
Age (years, mean ± SD) 41 ± 10.5
Disease duration (years, mean ± SD) 7.9 ± 8.1
Race (% white) 95
Follow-up time (months, mean ± SD) 44.7 ± 29.4
EDSS (mean ± SD) 1.22 ± 1.08
Pyramidal scale (mean ± SD) 0.61 ± 0.82
Cerebellar scale (mean ± SD) 0.28 ± 0.66
Brainstem scale (mean ± SD) 0.15 ± 0.43
Sensory scale (mean ± SD) 0.53 ± 0.77
Bowel bladder scale (mean ± SD) 0.27 ± 0.56
Mental scale (mean ± SD) 0.17 ± 0.49
Visual scale (mean ± SD) 0.22 ± 0.66
T r e a t m e n t( %I F N ,%G A ,%o t h e r ,%
untreated) 29.7, 30.9, 7.2, 32.2
EDSS: expanded disability status scale, IFN: all forms of interferon-𝗽,G A :
glatiramer acetate, other: natalizumab, rituximab, cyclophosphamide, dacli-
zumab, mycophenolate mofetil, mitoxantrone, or combination treatment.
1843 MS patients with at
least one clinical CLIMB
visits
929 patients had at least 2
eligible for the study
488 patients had diagnosis
other than RRMS or CIS at
baseline
1355 patients had RRMS
or CIS diagnosis at
baseline
396 patients had less than 1325 patients had EDSS <6
at baseline
30 patients had EDSS ≥6
at baseline
postbaseline visits to be
2 postbaseline visits
Figure 1: Flow chart for selection of patients included in study.
at two consecutive visits. These increases were (D1) increase
of 0.5 on the EDSS, (D2) increase of 1, (D3) increase of 1.5,
and (D4) increase of 1.5 for patients with baseline EDSS = 0,
a n di n c r e a s eo f1f o rp a t i e n t sw i t hb a s e l i n e1≤ EDSS ≤ 5.5.
Two consecutive visits corresponded to six months for the
majority of patients who experienced progression (339/392
for patients who experienced sustained progression using
D1). For theremainingsubjects, thetwo visitswere separated
by12(𝑛=4 0 ),18(𝑛=8 ),or24ormore(𝑛=5 )months;itwasMultiple Sclerosis International 3
assumedthattheEDSSlevelsobservedatthesevisitswerethe
s a m ea sw o u l dh a v eb e e no b s e rv e da tt h e6 - m o n t hv i s i t .
In addition, several definitions based on the FS scores
were investigated. First, sustained progression on each FS
scale was investigated based on a one-point increase on
the scale: (D5) pyramidal, (D6) cerebellar, (D7) brainstem,
(D8) sensory, (D9) bowel-bladder, (D10) mental, and (D11)
visual. As before, progression was required to be sustained
for 2 consecutive visits. The other symptoms’ scale was not
considered in our analysis. Since sustained progression on
the EDSS represents one potential set of changes on the FS
scales,fourotherpotentialcombinationsoftheFSscoreswere
considered. For the first two, the time to sustained progres-
sionwasdefinedasthetimetothefirst sustainedprogression
on any of the FS scales. Then, progression was identified as
sustained for the remainder of followup if (D12) any FS scale
continued to show progression or (D13) the first FS scale
continuedtoshowprogression.Thefinaltwodefinitionsused
thesumoftheFSscalesanddefinedsustainedprogressionas
an increase of (D14) two points in the sum of the FS scales
or (D15) three points in the sum of the FS scales. Although
previous work has demonstrated the potential pitfalls of
summing the FS scores especially late in the scale [12]a n d
summing the scale is not advocated by the originator of the
scale [1], these two definitions were assessed to determine if
they were more sensitive to irreversible disease progression
than the other definitions in the low end of the EDSS scale
where the disadvantages of summing are less clear.
2.3. Statistical Analysis. AK a p l a n - M e i e rc u r v ef o rt h et i m e
to sustained progression was created for each definition. For
definitions based on the EDSS, the FS scales associated with
the sustained progression were also determined. In addition
to the descriptive characteristics, the effect of baseline EDSS
score or FS score on the time to sustained progression was
investigated using a Cox proportional hazards model. In
each case, the baseline EDSS or FS scores were treated as a
continuous predictor, and the model was refit including only
patients with EDSS ≤ 3.5 at baseline.
To investigate the long-term behavior of each measure
of sustained progression, each patient was classified based
on whether sustained progression was maintained for the
rest of followup. The proportion of patients who maintained
sustained progression throughout followup was compared
across the definitions. In addition, the effect of followup
length and baseline functional score on the probability of
maintaining sustained progression was investigated using
logistic regression.
Two potential explanations for failing to maintain pro-
gression are the presence of relapses and changes in the
provider rating the patient. To assess the impact of relapses,
all visits classified during a relapse by the treating provider
were removed, and sustained progression was investigated
using only the nonrelapse visits. The same analyses as above
were completed. To assess the impact of changing providers
on maintaining sustained progression, the provider at the
time of sustained progression was compared to the provider
at the time of reversion to determine if a provider change
had occurred. As a comparison group, the provider at the
time of sustained progression was compared to the provider
atlastvisitforthepatientswhodidnotrevert.Theproportion
of patients who changed provider was compared in the two
groups using Fisher’s exact test to determine if provider
changes were associated with reversion.
3. Results
3.1. Time to Sustained Progression. Using the EDSS-based
definitions, between 15.8% and 42.2% of patients were
classified as having sustained progression during followup
(Table 2), and the time to sustained progression and the
corresponding 95% confidence interval are presented in
Figure 2. As expected, the time to progression was fastest for
D1 and slowest for D3. When sustained progression on each
of the individual FS was investigated, the time to sustained
progression varied widely across the scales (Figure 3). The
time to sustained progression was fastest for the pyramidal
and sensory scales and slowest for the brainstem and visual
scales. These results demonstrated that progression differen-
tiallyaffectsspecificFS.Finally,forthealternativedefinitions
of sustained progression based on combinations of the FS
scales (D12–D15), the time to sustained progression was
fastest for those based on progression on any scale (Figure 3).
The time to sustained progression based on a two point
increaseinthesumoftheFSscaleswassimilartothetimefor
an EDSS increase of 1, and the time to a three-point increase
inthesumwassimilartothetimeforanEDSSincreaseof1.5.
Across all EDSS definitions, the most common cause of
s u s t a i n e dp r o g r e s s i o nw a sa ni n c r e a s ei ns e n s o r yo rp y r a m i -
dal symptoms (Table 3). For D1 and D2, between 30% and
41% of patients experienced progression on the pyramidal
or sensory scales; while for D3 and D4, between 42% and
57% of patients experienced progression for each of these
systems. D1 and D2 were also associated with a greater than
15% chance of progression on no FS scales even though
EDSS progression was observed, while progression on no FS
scales was much less common for D3 and D4. Finally, over
5 0 %o fp a t i e n t sw h op r o g r e s s e df o rD 3a n dD 4h a dd i s e a s e
p r o g r e s s i o no nm u l t i p l eF Ss c a l e s ,d e m o n s t r a t i n gt h a tt h e
p r o g r e s s i o nw a so ft e nd u et om u l t i p l ed o m a i n s .
3.2. Effect of Baseline Disability Status on Time to Sustained
Progression. Baseline disability level had an important effect
onthetimetosustainedprogression(Figure 4).Inparticular,
patients with a baseline EDSS= 0 had a faster time to sus-
tainedprogressionforalloftheprogressiondefinitionsbased
on changes in the EDSS compared to patients with baseline
EDSS between 1 and 3.5. This result was particularly striking
whenthecriterionwasD2(Figure 4(b)).Adecreasinghazard
of progression with increasing baseline EDSS was observed
for all definitions, and the effects were very strong for D1–
D3 (𝑃 < 0.0001)a n ds i g n i fi c a n tf o rD 4( 𝑃 = 0.03). These
effectswereevenstrongerwhenbaselineEDSSwasrestricted
to be less than 4. When baseline EDSS was less than 4, the
hazard of progression decreased by a factor of 0.51 (95% CI:
0.44, 0.59) for each one-point increase in the EDSS for D2
a n d0 . 8 3( 9 5 %C I :0 . 7 2 ,0 . 9 6 )f o rD 4 ;t h eh a z a r dr a t i o sf o rt h e
other definitions were between these values.4 Multiple Sclerosis International
Table 2: Patients who met each definition of sustained progression during followup.
Patients with
sustained progression
Patient with sustained
progression
and subsequent visits
Patients who always progressed
among those with subsequent
visits
Number Percent of all
patients Number
Percent of those
with sustained
progression
Number
Percent of those
with subsequent
visits
EDSS
(D1) Increase of 0.5 392 42.2 315 80.4 137 43.5
(D2) Increase of 1 278 29.9 225 80.9 98 43.6
(D3) Increase of 1.5 147 15.8 120 81.6 61 50.8
(D4) Increase of 1/increase 1.5 for
baseline EDSS = 0 212 22.8 169 79.7 73 43.2
Functional system
(D5) Pyramidal function 217 23.4 179 82.5 53 29.6
(D6) Cerebellar function 120 12.9 94 78.3 29 30.9
(D7) Brainstem function 89 9.6 62 69.7 13 21
(D8) Sensory function 271 29.2 226 83.4 75 33.2
(D9) Bowel bladder function 179 19.3 135 75.4 38 28.1
(D10) Mental function 161 17.3 112 69.6 40 35.7
(D11) Visual function 91 9.8 73 80.2 16 21.9
Combination of functional system
(D12) Any FS 536 57.7 433 80.8 228 52.7
(D13) First FS 536 57.7 433 80.8 122 28.2
(D14) Sum of subscales increase of 2 243 26.2 187 77 85 45.5
(D15) Sum of subscales increase of 3 148 15.9 111 75 49 44.1
A total of 929 patients contributed to the analysis. EDSS: expanded disability status scale.
Table 3: Proportion of patients who experienced sustained increases in functional systems associated with sustained progression on the
EDSS.
(D1) Increase of 0.5
on the EDSS
(D2) Increase of 1
on the EDSS
(D3) Increase of 1.5
on the EDSS
(D4) Increase of
1/1.5 on the EDSS
based on baseline
EDSS
Total progressed 392 278 147 212
Number (%) progressed on pyramidal scale 119 (30.4) 96 (34.5) 65 (44.2) 88 (41.5)
Number (%) progressed on cerebellar scale 40 (10.2) 27 (9.7) 25 (17.0) 27 (12.7)
Number (%) progressed on brainstem scale 26 (6.6) 21 (7.6) 19 (12.9) 21 (9.9)
Number (%) progressed on sensory scale 140 (35.7) 113 (40.6) 83 (56.5) 104 (49.1)
Number (%) progressed on bowel bladder scale 66 (16.8) 55 (19.8) 39 (26.5) 55 (25.9)
Number (%) progressed on mental scale 59 (15.1) 46 (16.5) 31 (21.1) 44 (20.8)
Number (%) progressed on visual scale 32 (8.2) 26 (9.4) 20 (13.6) 27 (12.7)
Number (%) progressed on multiple scales 124 (31.6) 105 (37.8) 92 (62.6) 118 (55.7)
Number (%) progressed on no scale 81 (20.7) 47 (16.9) 5 (3.4) 15 (7.1)
EDSS: expanded disability status scale.
Faster time to sustained progression in patients with
lower baseline disability was also observed on several FS
(Figure 5). A statistically significant increase in the hazard
over all values of the baseline FS score was observed for the
pyramidal (𝑃 = 0.016), sensory (𝑃 < 0.0001), bowel/bladder
(𝑃 = 0.002), and mental scale (𝑃 = 0.037). For the cerebellar
scale,thetimetosustainedprogressionwasfastestinpatients
with a baseline score of 1, and this group was significantly
faster than the remaining patients (𝑃 = 0.037,l o g - r a n kt e s t ) .
3.3. Maintaining Sustained Progression. Since patients
who experience sustained progression may not have truly
progressed, Table 2 also presents the proportion of patients
withsustainedprogressionwhomaintainedtheelevatedlevelMultiple Sclerosis International 5
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Figure 2: Time to sustained progression for EDSS definitions. EDSS: expanded disability status scale. Each Kaplan-Meier plot presents the
time to sustained progression using a specific definition: (a) top left: increase of 0.5 on the EDSS sustained for two visits (D1); (b) top right:
increase of 1 on the EDSS sustained for two visits (D2); (c) bottom left: increase of 1.5 on the EDSS sustained for two visits (D3); (d) bottom
right: increase of 1.5 for baseline EDSS = 0 and increase of 1 for baseline EDSS≥1 sustained for two visits (D4).
on the EDSS for the remainder of followup. For definitions
based on the EDSS, the morestringent rules were morelikely
to result in patients maintaining sustained progression, but
fewer than 51% of patients maintained sustained progression
for each definition.
Although sustained progression was observed on each
FS, the proportion of patients who maintained sustained
progression on any FS was lower than the proportion using
definitions based on the EDSS. In fact, only 21% of patients
who experienced sustained progression on the brainstem FS
maintainedtheelevatedlevelfortheremainderofsubsequent
followup. These results show that definitions of sustained
progression based on the FS scales are not sensitive to true
irreversible disability.
When sustained progression on any FS was investigated,
theproportionthatmaintainedsustainedprogressionwasthe
highest among any definition. At the same time, the cause
of the sustained progression could vary across time points.
When the first subscale with sustained progression was
required to remain elevated, the proportion that maintained
sustainedprogressionwasreducedbynearlyhalf(53%versus
28%). The sum of the FS definitions had a similar proportion
ofpeoplewhomaintainedtheelevatedlevelasthedefinitions
based on the EDSS.
Intermsofpredictorsofreversion,thetimeofsubsequent
followup was a significant predictor of reversion (𝑃 < 0.001
for each definition based on the EDSS), but baseline EDSS
was not a significant predictor in any model. In particular,
patients with longer followup were more likely to revert,
demonstrating that our estimated reversion proportions may
be underestimated compared to if we had longer followup
on all patients. Similar trends were observed for definitions
based on the FS.
3.4. Impact of Relapse or Provider Changes on Improvement.
Potential explanations for reversions are the presence of
relapses or a change in the rating provider. When visits
classified during a relapse were removed from the analysis,
the results were unchanged. In particular, the proportion of
patients who experienced sustained progression was slightly
less, but a large percentage of patients still failed to main-
tain the elevated EDSS or FS scores for the remainder of
followup (data not shown). Changing provider was also not
significantly associated with reversion since patients who6 Multiple Sclerosis International
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Figure 3: Time to sustained progression for functional system score definitions. Each graph represents a different definition of sustained
progression: top row (from left to right)—increase on pyramidal subscale (D5), increase on cerebellar subscale (D6), increase on brainstem
subscale (D7), increase on sensory subscale (D8); middle row (from left to right)—increase on bowel-bladder subscale (D9), increase on
mental subscale (D10), increase on visual subscale (D11), increase on any subscale (D12); bottom row (from left to right)—increase in first
subscale (D13), increase of 2 in the sum of the subscales (D14), increase of 3 in the sum of the subscales (D15).
revertedwerenotsignificantlymorelikelytochangeprovider
compared to patients who failed to revert (Fisher’s exact test
𝑃 > 0.05 for all tests). Therefore, although a large percentage
of our patients who experienced sustained progression failed
to maintain progression, relapses and changes in provider
were not the main reason for the poor performance of these
definitions.
4. Discussion
The analysis of sustained progression in our observational
cohort demonstrated that sustained progression by any def-
inition occurs infrequently in the disease modifying therapy
era. In addition, sustained progression on the EDSS was only
maintained for the remainder of followup for at most 50% of
patients, which is consistent with previous findings from the
placebo arms of clinical trials [8]. Therefore, the use of any
definition presented here as an outcome for clinical trials or
observationalstudieshasuncertainclinicalmeaninginterms
of long-term disease progression. A possible reason for the
poor performance is the requirement of an elevated EDSS for
o n l yt w ov i s i t st oq u a l i fya ss u s t a i n e d .A l t e r n a t i v ed e fi n i t i o n s
could require elevated EDSS for at least three visits, which
c o r r e s p o n d st ot w e l v em o n t h si nC L I M Bp a t i e n t s .A l lo ft h e
previous analyses were also completed requiring progression
to be sustained for three consecutive visits, but the results
observed were largely unchanged.
One potential explanation for the poor performance of
the definitions of progression in this RRMS cohort is the
limited relationship between the early phase of the disease
and long-term disease progression. A recent study based on
the London Ontario cohort demonstrated that only a high
relapse rate very early in the disease course was associated
withaworseprognosisintermsofprogression[13].Asample
of progressive patients from this cohort showed that the rate
of progression was roughly the same in patients with no,Multiple Sclerosis International 7
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Figure 4: Time to sustained progression stratified by baseline EDSS value. Colors of Kaplan-Meier curve are based on baseline EDSS value:
EDSS = 0: red, EDSS = 1/1.5: orange, EDSS = 2/2.5: green, EDSS = 3/3.5: blue, EDSS = 4–5.5: black. Progression definition for each plot:
(a) D1, (b) D2, (c) D3, and (d) D4.
one, or many relapses in the early phase of the disease [14].
These results demonstrate the lack of association between
relapserateandlong-termdiseaseprogression.Toaddressthe
potential problems caused by transient increases in the EDSS
due to relapses, the concept of sustained progression was
developed,buttheinabilityofanyofthedefinitionspresented
in this paper to identify true disease progression provides
further evidence that short-term changes in the EDSS are
likely not identifying true irreversible disability.
ThedefinitionsofsustainedprogressionrequiretheEDSS
to remain elevated for consecutive visits to ensure that the
increase is not due solely to a relapse. At the same time, the
presence of a relapse at the time of sustained progression
mightexplainsomeofthereversionsobservedinourdataset.
When all observed EDSS measurements taken during a
relapseaccordingthescoringprovider,thehighprobabilityof
reversionremained.Therefore,thereversionsobservedinour
sample were not due to relapses and likely show true short-
term disease fluctuations.
To address the problem with maintaining sustained
progression on the EDSS, sustained progression on each
of the FS scales was investigated. Since each FS measures
only one system, it was hypothesized that definitions based
on a specific FS scale would be less subject to fluctuations.
Surprisingly, sustained progression on any individual FS was
actuallylesssensitivetotruechangethantheEDSS.Lessthan
half of patients who experienced sustained progression on a
specific FS maintained the progression. Therefore, using the
FS scores for future studies does not appear to allow better
measurement of irreversible worsening.
The effect of baseline EDSS on the time to sustained
progression has important implications for future studies
because the probability of sustained progression is a function
of the starting EDSS value. Several clinical trials have already
incorporated the difference in probability of progression for
patients with an EDSS = 0 through the use of D4 [6, 7],
but our results demonstrate that the problem persists for
other EDSS values. Therefore, any imbalance in the baseline
EDSS may lead to biased estimates of group differences if
EDSS is not appropriately controlled in statistical models.
The very low chance of sustained progression for patients
with an EDSS of 3–3.5 may also be due to regression to the
mean/measurement error. Regression to the mean is a well-
described phenomenon in MS clinical trials with regard to
disease activity [15], but this is rarely considered in analysis
of sustained progression.8 Multiple Sclerosis International
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Figure5:Timetosustainedprogressionstratifiedbybaselinefunctionalsystemscorevalue.Colorsindicatebaselinefunctionalsystemscore:
score = 0: red, score = 1: orange, score= 2: green, score = 3: blue, score≥ 4: purple. Progression definition for each plot: top row: D5 to D8;
bottom row: D9 to D11.
Our study has several limitations that warrant further
discussion. One limitation is that different neurologists
scored patients at different time points over the course of the
study. The interrater reliability of the EDSS is lower than the
intraraterreliabilityoftheEDSS[16],sosomeoftheobserved
c h a n g e sm a yb ed u et oc h a n g e si nr a t e r .A l t h o u g hi ti s
impossibletoknowwhattheEDSSwouldhavebeenscoredif
the same rater was used throughout the study, changing rater
was not significantly associated with maintaining sustained
progression in this study. This result does not imply that rater
had no effect on EDSS score, but it does demonstrate that
thereversionsobservedinourstudywerenotexclusivelydue
to rater changes. A second limitation is that no restrictions
were placed on treatment regimens followed by patients.
Lastly, our results reflect those of patients enrolled in the
CLIMB study. Although patients in the CLIMB study are
treatedinthesamemannerasotherpatientswithinourclinic,
which, to our knowledge is in line with standard practices of
tertiary MS Centers in the United States, it is possible that
this population may differ from others seen within different
practice settings or different geographic locations.
In conclusion, no definition of sustained progression
based on the EDSS or the component FS scores was sensitive
forirreversible progressionof the disease. Since changing the
definitionfailedtoleadtoimprovedperformance,alternative
measures of disease progression/severity must be found to
better classify patients with short-term disease progression.
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